Article
Hematology
Leanne R. O'Sullivan, Gerardene Meade-Murphy, Oonagh M. Gilligan, Vitaliy Mykytiv, Paul W. Young, Mary R. Cahill
Summary: Thrombotic events are common in patients with MM, SM, and MGUS. Platelet hyperactivation is prevalent in both MGUS and SM/MM patients, potentially related to hyporesponsiveness. Further investigation of the predictive and prognostic value of platelet hyperactivation in such patients is warranted.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Mara M. Epstein, Yanhua Zhou, Maira A. Castaneda-Avila, Harvey J. Cohen
Summary: Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma, is present in over 5% of adults aged 70 and older. Our study examined patterns of multimorbidity among MGUS patients and found higher prevalence of certain comorbidities among MGUS cases, indicating the need for additional investigation.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Jihad Aljabban, Sharjeel Syed, Saad Syed, Michael Rohr, Mohamed Mukhtar, Hisham Aljabban, Francesca Cottini, Mohammed Mohammed, Tiffany Hughes, Taylor Gonzalez, Maryam Panahiazr, Dexter Hadley, Don Benson
Summary: This study compares the transcriptomes of MGUS and MM, finding specific genes and pathways involved in MGUS and new signaling pathways and gene activity in MM. Certain upregulated genes in MM may play a crucial role in the progression from benignity to malignancy and could serve as drug targets or novel biomarkers for risk of progression. Overall, these findings are important for further understanding the etiology of MGUS and MM.
Article
Oncology
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde, Michael Emanuel, Ani Petrosyan, Manisha Bhutani, Katherine R. Calvo, Alina Dulau-Florea, Mary Kwok, Min-Jung Lee, Sunmin Lee, Liza Lindenberg, Sham Mailankody, Elisabet Manasanch, Irina Maric, Esther Mena, Nisha Patel, Nishant Tageja, Jane B. Trepel, Baris Turkbey, Hao-Wei Wang, Weixin Wang, Constance Yuan, Yong Zhang, Raul Braylan, Peter Choyke, Maryalice Stetler-Stevenson, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren
Summary: Treatment with novel triplet regimens such as KRd and lenalidomide maintenance therapy for high-risk smoldering myeloma may significantly delay the progression to symptomatic multiple myeloma, altering the natural history of the disease. Further randomized clinical trials are needed to confirm the favorable benefit-to-risk profile observed in this phase 2 trial.
Article
Hematology
Harriet Ghansah, Ildiko Beke Debreceni, Laszlo Varoczy, Laszlo Rejto, Linda Loczi, Zsuzsa Bagoly, Janos Kappelmayer
Summary: Patients with MM and MGUS have increased thrombotic risk, and APC has different effects on thrombin generation in these groups.
THROMBOSIS RESEARCH
(2023)
Article
Oncology
Romanos Sklavenitis-Pistofidis, Michelle P. Aranha, Robert A. Redd, Joanna Baginska, Nicholas J. Haradhvala, Margaret Hallisey, Ankit K. Dutta, Alexandra Savell, Shohreh Varmeh, Daniel Heilpern-Mallory, Sylvia Ujwary, Oksana Zavidij, Francois Aguet, Nang K. Su, Elizabeth D. Lightbody, Mark Bustoros, Sabrin Tahnri, Tarek H. Mouhieddine, Ting Wu, Lea Flechon, Shankara Anand, Jacalyn M. Rosenblatt, Jeffrey Zonder, James J. Vredenburgh, Adam Boruchov, Manisha Bhutani, Saad Z. Usmani, Jeffrey Matous, Andrew J. Yee, Andrzej Jakubowiak, Jacob Laubach, Salomon Manier, Omar Nadeem, Paul Richardson, Ashraf Z. Badros, Maria-Victoria Mateos, Lorenzo Trippa, Gad Getz, Irene M. Ghobrial
Summary: This study found that early treatment with EloLenDex is safe and effective for high-risk SMM patients, and provides a comprehensive characterization of alterations in immune cell composition and TCR repertoire diversity in patients. The study also revealed that the similarity of a patient's immune cell composition to that of healthy donors may have prognostic relevance at diagnosis and after treatment.
Article
Medicine, General & Internal
Weiguo Lu, Jiaming Liu, Man Luo, Mingfeng Xiao
Summary: The relationship between Monoclonal Gammopathy of undetermined significance (MGUS) and Multiple Myeloma (MM) was explored using bioinformatics methods. A total of 227 genes associated with both MGUS and MM were identified, including core genes such as TNF, IL-1B, IL-6, CSF2, CXCL8, and IL-10. Eight candidate drugs were selected as potential interventions to prevent the progression from MGUS to MM.
PAKISTAN JOURNAL OF MEDICAL SCIENCES
(2023)
Article
Oncology
Gregorio Barila, Laura Pavan, Susanna Vedovato, Tamara Berno, Mariella Lo Schirico, Massimiliano Arangio Febbo, Antonella Teramo, Giulia Calabretto, Cristina Vicenzetto, Vanessa Rebecca Gasparini, Anna Fregnani, Sabrina Manni, Valentina Trimarco, Samuela Carraro, Monica Facco, Francesco Piazza, Gianpietro Semenzato, Renato Zambello
Summary: The immune system of patients with active Multiple Myeloma is significantly modulated by therapy, with treatments such as autologous stem cell transplantation and Lenalidomide leading to a dominant cytotoxic response that contributes to the anti-Myeloma effect of these regimens.
FRONTIERS IN ONCOLOGY
(2021)
Review
Hematology
Heinz Ludwig, Pieter Sonneveld, Thierry Facon, Jesus San-Miguel, Herve Avet-Loiseau, Mohamad Mohty, Maria-Victoria Mateos, Philippe Moreau, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, Monika Engelhardt, Christoph Driessen, Gordon Cook, Melitios A. Dimopoulos, Francesca Gay, Hermann Einsele, Michel Delforge, Jo Caers, Katja Weisel, Graham Jackson, Laurent Garderet, Niels van de Donk, Xavier Leleu, Hartmut Goldschmidt, Meral Beksac, Inger Nijhof, Martin Schreder, Niels Abildgaard, Roman Hajek, Niklas Zojer, Efstathios Kastritis, Annemiek Broijl, Fredrik Schjesvold, Mario Boccadoro, Evangelos Terpos
Summary: Patients with multiple myeloma are at increased risk of infection and mortality related to SARS-CoV-2 virus, and may have suboptimal immune response to vaccination, highlighting the importance of monitoring and adapting vaccination strategies for this vulnerable population.
LANCET HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Vanessa Piechotta, Nicole Skoetz, Monika Engelhardt, Hermann Einsele, Hartmut Goldschmidt, Christof Scheid
Summary: This clinical practice guideline focuses on the care modalities that can be offered in addition to systemic antineoplastic therapy for multiple myeloma. It recommends using the International Staging System (ISS) for staging MM, using whole-body computed tomography to determine the extent of skeletal involvement in symptomatic cases, and considering biological age in treatment decision-making. For suitable patients, initial treatment with high-dose therapy and combination therapies for relapse can achieve longer progression-free survival.
DEUTSCHES ARZTEBLATT INTERNATIONAL
(2022)
Article
Hematology
Thoger Nielsen, Soren Risom Kristensen, Henrik Gregersen, Elena Manuela Teodorescu, Shona Pedersen
Summary: This study demonstrated that patients with MGUS and MM exhibit hypercoagulability with increased thrombin generation, possibly due to higher TF and procoagulant phospholipids activity. MM patients also showed elevated levels of cf-DNA, indicating a potential association with procoagulant NETs activity.
THROMBOSIS RESEARCH
(2021)
Article
Medicine, Research & Experimental
Jana Jakubikova, Danka Cholujova, Gabor Beke, Teru Hideshima, Lubos Klucar, Merav Leiba, Krzysztof Jamroziak, Paul G. Richardson, Efstathios Kastritis, David M. Dorfman, Kenneth C. Anderson
Summary: By using mass cytometry analysis, we characterized the plasma cells and B cell lymphopoiesis in bone marrow samples from patients with different stages of multiple myeloma (MM), revealing various heterogeneities. We found overexpression of MMSET, Notch-1, and CD47 in malignant plasmablasts and plasma cells, and variations in the upregulation of B cell signaling regulators and aberrant markers were associated with different clinical outcomes. Furthermore, we identified elevated levels of various markers from hematopoietic stem cells to plasma cells, with variably modulated expression of B cell development regulators and stemness-controlling regulators. This study highlights the importance of precise molecular profiling in MM using CyTOF technology to understand disease heterogeneity and predict prognosis.
Article
Hematology
Jithma P. Abeykoon, Julia Vaxman, Sanjay V. Patel, Shaji Kumar, Gabriella C. Malave, Kimberly S. Young, Sikander Ailawadhi, Jeremy T. Larsen, Angela Dispenzieri, Eli Muchtar, Wilson I. Gonsalves, Taxiarchis Kourelis, Nelson Leung, Rahma Warsame, Ronald S. Go, Leif Bergsagel, Martha Q. Lacy, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor
Summary: A study found that 75% of patients treated with Belantamab mafodotin (BLMF) for advanced multiple myeloma experienced ocular toxicity, with 69% developing keratopathy. Among patients who had to permanently discontinue or reduce BLMF treatment due to ocular toxicity, 70% experienced progression of multiple myeloma within 3 months.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Emma Pauline Kreutzer, Sandra Sauer, Mark Kriegsmann, Henrike Staemmler, Gerlinde Egerer, Katharina Kriegsmann
Summary: This analysis evaluated the online health information related to monoclonal gammopathy of undetermined significance (MGUS), finding a generally low quality of internet resources with a risk of misinformation. Websites provided by scientific/governmental organizations had a higher content level.
Article
Oncology
Roberia Mendonca de Pontes, Juan Flores-Montero, Luzalba Sanoja-Flores, Noemi Puig, Roberto J. Pessoa de Magalhaes, Alba Corral-Mateos, Anna Beatriz Salgado, Omar Garcia-Sanchez, Jose Perez-Moran, Maria-Victoria Mateos, Leire Burgos, Bruno Paiva, Jeroen te Marvelde, Vincent H. J. van der Velden, Carlos Aguilar, Abelardo Barez, Aranzazu Garcia-Mateo, Jorge Labrador, Pilar Leoz, Carmen Aguilera-Sanz, Brian Durie, Jacques J. M. van Dongen, Angelo Maiolino, Elaine Sobral da Costa, Alberto Orfao
Summary: The study found that B-cell regeneration during therapy in multiple myeloma patients is not significantly associated with patient outcomes, and therapy and hemodilution impact bone marrow B-cell recovery to some extent.
Article
Medical Laboratory Technology
Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Bene, Peter Valent, Jeroen te Marvelde, Orianne Wagner-Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink-Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiss, Wolfgang Kern, Arjan van de Loosdrecht
Summary: This article reviews the progress of flow cytometry (FCM) in the diagnosis of myelodysplastic syndrome (MDS) in recent years, and provides optimal methods and recommendations for sample processing, antibody panels and fluorochromes, and current hardware technologies. These recommendations will facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients, but further standardization and harmonization are needed.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Elisabeth Weiss, Wencke Walter, Manja Meggendorfer, Constance Baer, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern
Summary: Myelodysplastic syndromes (MDS) is a group of diseases, and we have identified a specific immunophenotype and genetic mutations in some MDS cases, with a consistent gene expression profile. These findings may contribute to defining a new sub-entity of MDS.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Orianne Wagner-Ballon, Peter Bettelheim, Jeroen Lauf, Frauke Bellos, Matteo Della Porta, Erica Travaglino, Dolores Subira, Irene Nuevo Lopez, Sihem Tarfi, Theresia M. Westers, Ulrika Johansson, Katherina Psarra, Serafeim Karathanos, Sergio Matarraz, Enrique Colado, Monali Gupta, Robin Ireland, Wolfgang Kern, Arjan A. Van de Loosdrecht
Summary: This multicenter study demonstrates the robustness of the monocyte assay in distinguishing chronic myelomonocytic leukemia from other causes of monocytosis. It also confirms the possibility of using this assay in bone marrow samples.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Arjan A. Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. Marvelde, Sergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Marie C. Bene, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland
Summary: This article discusses the rationale for including flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group. The WHO 2016 classification acknowledges the contribution of FCM in the diagnosis of MDS and its potential usefulness in prognostication, prediction, therapy evaluation, and patient follow-up.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Genetics & Heredity
Constance Baer, Shunsuke Kimura, Mitra S. Rana, Andrew B. Kleist, Tim Flerlage, David J. Feith, Peter Chockley, Wencke Walter, Manja Meggendorfer, Thomas L. Olson, HeeJin Cheon, Kristine C. Olson, Aakrosh Ratan, Martha-Lena Mueller, James M. Foran, Laura J. Janke, Chunxu Qu, Shaina N. Porter, Shondra M. Pruett-Miller, Ravi C. Kalathur, Claudia Haferlach, Wolfgang Kern, Elisabeth Paietta, Paul G. Thomas, M. Madan Babu, Thomas P. Loughran, Ilaria Iacobucci, Torsten Haferlach, Charles G. Mullighan
Summary: This study reveals the hallmark of a distinct subset of chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) through somatic mutations in the chemokine gene CCL22. These mutations result in biased signaling downstream of the chemokine receptor, leading to increased cell chemotaxis and NK cell proliferation through interactions with the hematopoietic microenvironment.
Article
Medicine, General & Internal
Vera Adema, Laura Palomo, Wencke Walter, Mar Mallo, Stephan Hutter, Thomas La Framboise, Leonor Arenillas, Manja Meggendorfer, Tomas Radivoyevitch, Blanca Xicoy, Andrea Pellagatti, Claudia Haferlach, Jacqueline Boultwood, Wolfgang Kern, Valeria Visconte, Mikkael Sekeres, John Barnard, Torsten Haferlach, Francesc Sole, Jaroslaw P. Maciejewski
Summary: This study provides an in-depth analysis of myeloid neoplasia caused by haploinsufficiency resulting from deletion of the long arm of chromosome 5 (del(5q)). The research identifies the importance of del(5q) genes in the development of the disease and establishes a gene signature that distinguishes del(5q) cases from diploid cases. The study also reveals the heterogeneity of gene expression within del(5q) patients and uncovers the balance of specific genes that drive clonal expansion.
Editorial Material
Medical Laboratory Technology
Wolfgang Kern, Arjan van de Loosdrecht
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Wolfgang Kern, Theresia M. Westers, Frauke Bellos, Marie Christine Bene, Peter Bettelheim, Lisa Eidenschink Brodersen, Kate Burbury, Sung-Chao Chu, Matthew Cullen, Matteo Della Porta, Alan Stewart Dunlop, Ulrika Johansson, Sergio Matarraz, Uta Oelschlaegel, Kiyoyuki Ogata, Anna Porwit, Frank Preijers, Katherina Psarra, Leonie Saft, Dolores Subira, Elisabeth Weiss, Vincent H. J. van der Velden, Arjan van de Loosdrecht
Summary: This study evaluated the use of pre-defined flow cytometric markers in the diagnosis of MDS and CMML. The results showed that flow cytometry had a high concordance with the diagnosis of MDS, and could identify cases "in agreement with MDS". Furthermore, the study suggested that a 3% cut-off for myeloid progenitor cells in flow cytometry was more appropriate than the cytomorphologically defined cut-off of 5%.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Letter
Oncology
Constance Baer, Sandra Huber, Stephan Hutter, Manja Meggendorfer, Niroshan Nadarajah, Wencke Walter, Uwe Platzbecker, Katharina S. Goetze, Wolfgang Kern, Torsten Haferlach, Gregor Hoermann, Claudia Haferlach
Correction
Oncology
Janine Mueller, Wencke Walter, Claudia Haferlach, Heiko Mueller, Irene Fuhrmann, Martha-Lena Mueller, Henning Ruge, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Anna Stengel
Letter
Oncology
Janine Mueller, Wencke Walter, Claudia Haferlach, Heiko Mueller, Irene Fuhrmann, Martha-Lena Mueller, Henning Ruge, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Anna Stengel
Article
Oncology
Maki Sakuma, Piers Blombery, Manja Meggendorfer, Claudia Haferlach, Markus Lindauer, Uwe M. Martens, Wolfgang Kern, Torsten Haferlach, Wencke Walter
Summary: The study identified three somatic mutations in the UBA1 gene that are associated with the development of VEXAS syndrome. Additionally, the analysis revealed several putative somatic variants in UBA1 that may contribute to myeloid malignancies, particularly in patients with vacuoles or immunodysregulatory symptoms.
Letter
Oncology
Sandra Huber, Torsten Haferlach, Heiko Mueller, Manja Meggendorfer, Stephan Hutter, Gregor Hoermann, Constance Baer, Wolfgang Kern, Claudia Haferlach
Article
Oncology
Sandra Huber, Constance Baer, Stephan Hutter, Frank Dicker, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Gregor Hoermann
Summary: According to the new classification standards, there have been changes in the diagnosis of leukemia patients, with an increase in the proportion of certain subtypes and the largest group still being genetically defined. The new classifications focus on genetics-based definitions with similar basic concepts and a large degree of agreement.
Letter
Oncology
Sandra Huber, Constance Baer, Stephan Hutter, Frank Dicker, Irene Fuhrmann, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Gregor Hoermann
